Pfizer 향후 성장

Future 기준 점검 1/6

Pfizer (는) 각각 연간 7.3% 및 7.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 7.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.1% 로 예상됩니다.

핵심 정보

7.3%

이익 성장률

7.30%

EPS 성장률

Pharmaceuticals 이익 성장	16.0%
매출 성장률	7.8%
향후 자기자본이익률	17.13%
애널리스트 커버리지	Low
마지막 업데이트	14 Nov 2025

최근 향후 성장 업데이트

Recent updates

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 28%

May 28

Pfizer (NSE:PFIZER) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

May 26

Pfizer Limited's (NSE:PFIZER) Share Price Not Quite Adding Up

Mar 03

Some Confidence Is Lacking In Pfizer Limited's (NSE:PFIZER) P/E

Nov 28

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Aug 31

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Aug 07

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

May 25

Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet

Feb 13

Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share Price

Jan 17

Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly

Mar 15

A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)

Jul 20

Pfizer (NSE:PFIZER) Could Easily Take On More Debt

Mar 29

Calculating The Fair Value Of Pfizer Limited (NSE:PFIZER)

Feb 07

이익 및 매출 성장 예측

NSEI:PFIZER - 애널리스트 향후 추정치 및 과거 재무 데이터 (INR Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
3/31/2028	28,879	9,941	6,563	7,063	1
3/31/2027	26,555	8,332	5,771	6,162	2
3/31/2026	24,612	7,371	8,450	8,120	2
9/30/2025	23,753	8,393	8,804	9,098	N/A
6/30/2025	23,215	8,086	N/A	N/A	N/A
3/31/2025	22,814	7,676	6,316	6,598	N/A
12/31/2024	22,361	6,155	N/A	N/A	N/A
9/30/2024	22,381	6,179	4,014	4,165	N/A
6/30/2024	22,247	6,085	N/A	N/A	N/A
3/31/2024	21,932	5,513	2,379	2,568	N/A
12/31/2023	22,192	5,021	N/A	N/A	N/A
9/30/2023	23,010	5,228	4,322	5,040	N/A
6/30/2023	23,632	6,849	N/A	N/A	N/A
3/31/2023	24,248	6,239	2,907	3,557	N/A
12/31/2022	24,041	6,201	N/A	N/A	N/A
9/30/2022	24,583	6,133	1,341	1,493	N/A
6/30/2022	24,571	4,452	N/A	N/A	N/A
3/31/2022	26,110	6,126	6,518	6,671	N/A
12/31/2021	25,961	5,873	N/A	N/A	N/A
9/30/2021	25,137	5,847	7,018	7,147	N/A
6/30/2021	24,728	5,731	N/A	N/A	N/A
3/31/2021	22,404	4,976	4,096	4,273	N/A
12/31/2020	22,058	5,001	N/A	N/A	N/A
9/30/2020	21,505	4,979	4,129	4,004	N/A
6/30/2020	21,221	5,208	N/A	N/A	N/A
3/31/2020	21,517	5,091	3,211	3,232	N/A
12/31/2019	21,853	5,156	N/A	N/A	N/A
9/30/2019	21,609	5,085	1,760	1,716	N/A
6/30/2019	21,136	4,500	N/A	N/A	N/A
3/31/2019	20,815	4,291	N/A	978	N/A
12/31/2018	20,658	4,241	N/A	N/A	N/A
9/30/2018	20,085	3,794	N/A	N/A	N/A
6/30/2018	20,599	3,947	N/A	N/A	N/A
3/31/2018	19,685	3,601	N/A	3,318	N/A
12/31/2017	18,866	3,236	N/A	N/A	N/A
9/30/2017	19,215	2,987	N/A	N/A	N/A
6/30/2017	18,860	3,139	N/A	N/A	N/A
3/31/2017	19,663	3,368	N/A	3,288	N/A
12/31/2016	20,453	2,737	N/A	N/A	N/A
9/30/2016	20,595	2,711	N/A	N/A	N/A
6/30/2016	20,350	2,276	N/A	N/A	N/A
3/31/2016	20,123	3,050	N/A	3,455	N/A
12/31/2015	19,649	1,680	N/A	N/A	N/A
9/30/2015	19,334	1,460	N/A	N/A	N/A
6/30/2015	19,018	861	N/A	N/A	N/A
3/31/2015	18,531	698	N/A	1,135	N/A

애널리스트 향후 성장 전망

수입 대 저축률: PFIZER 의 연간 예상 수익 증가율(7.3%)이 saving rate(6.8%)보다 높습니다.

수익 vs 시장: PFIZER 의 연간 수익(7.3%)이 Indian 시장(16.4%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: PFIZER 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: PFIZER 의 수익(연간 7.8%)이 Indian 시장(연간 10.9%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: PFIZER 의 수익(연간 7.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: PFIZER의 자본 수익률은 3년 후 17.1%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/31 21:05
종가	2025/12/31 00:00
수익	2025/09/30
연간 수익	2025/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Pfizer Limited는 10명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Sriraam Rathi	Anand Rathi Shares and Stock Brokers Limited
null null	Anand Rathi Shares and Stock Brokers Limited
Rohit Bhat	Batlivala & Karani Securities India Pvt. Ltd.

Pfizer 향후 성장

Future 기준 점검 1/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 11% to ₹5,477

Price target decreased by 7.9% to ₹4,595

Price target decreased to ₹5,201

Price target decreased to ₹5,654

Price target decreased to ₹5,749

Recent updates

Pfizer Limited's (NSE:PFIZER) Price Is Out Of Tune With Earnings

Pfizer's (NSE:PFIZER) Solid Profits Have Weak Fundamentals

New major risk - Revenue and earnings growth

Second quarter 2026 earnings released: EPS: ₹41.32 (vs ₹34.61 in 2Q 2025)

Pinning Down Pfizer Limited's (NSE:PFIZER) P/E Is Difficult Right Now

First quarter 2026 earnings released: EPS: ₹41.91 (vs ₹32.94 in 1Q 2025)

New major risk - Revenue and earnings growth

Pfizer Limited Announces Directorate Changes

Full year 2025 earnings released: EPS: ₹168 (vs ₹121 in FY 2024)

Pfizer Limited to Report Q4, 2026 Results on May 30, 2026

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 28%

Pfizer (NSE:PFIZER) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Investor sentiment improves as stock rises 15%

Pfizer Limited, Annual General Meeting, Jul 21, 2025

Full year 2025 earnings released: EPS: ₹168 (vs ₹121 in FY 2024)

Pfizer Limited's (NSE:PFIZER) Share Price Not Quite Adding Up

Pfizer Limited Announces Completion of Second Term for Sunil Lalbhai as an Independent Director, Chairman of the Stakeholders' Relationship Committee and Risk Management Committee and Member of the Audit Committee

Third quarter 2025 earnings released: EPS: ₹27.89 (vs ₹28.42 in 3Q 2024)

Pfizer Limited Announces Resignation of Amit Sharma as Director

FeganScott Announces Class-Action Lawsuit Against Pfizer and Viatris

Some Confidence Is Lacking In Pfizer Limited's (NSE:PFIZER) P/E

Pfizer Limited Appoints Mr. Chetan Solse as India Legal Lead, Effective November 18, 2024

Pfizer Limited Announces Board and Committee Changes

Pfizer Limited Announces Executive Appointments, Effective November 7, 2024

Second quarter 2025 earnings released: EPS: ₹34.61 (vs ₹32.56 in 2Q 2024)

High number of new directors

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Pfizer Limited Approves to Declare A Dividend for the Financial Year Ended March 31, 2024

Dividend of ₹35.00 announced

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Pfizer Limited to Report Q2, 2025 Results on Nov 14, 2024

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Price target increased by 11% to ₹5,477

First quarter 2025 earnings released: EPS: ₹32.94 (vs ₹20.44 in 1Q 2024)

Pfizer Limited to Report Q1, 2025 Results on Jul 29, 2024

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024

Pfizer Limited to Report Q4, 2024 Results on May 17, 2024

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet

Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024

Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share Price

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors

Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)

Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023

Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead

Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023

New major risk - Revenue and earnings growth

Pfizer Limited Announces Change in Management, Effective September 1, 2023

Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023

Upcoming dividend of ₹40.00 per share at 0.9% yield

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited, Annual General Meeting, Aug 18, 2023

Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023

Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections

Price target decreased by 7.9% to ₹4,595

Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023

Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly

Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022)

Pfizer India Appoints Meenakshi Nevatia as CEO

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Insufficient new directors